Login to Your Account



Other News To Note


Tuesday, September 3, 2013
Genzyme Inc., a unit of Sanofi SA, of Paris, said the European Commission granted marketing authorization for Aubagio (teriflunomide) as a once-daily, oral therapy in relapsing remitting multiple sclerosis (RRMS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription